Focus: Praxis Precision Medicines is a Boston-based biotech focused on genetic neuroscience treatments, particularly in epilepsy, developmental encephalopathies, and neuropsychiatric disorders. The company is actively scaling with 27 open positions across clinical, manufacturing, and regulatory functions.
Profile data last refreshed 43m ago · AI intelligence enriched 2mo ago
Stable — net -1 jobs in 30d
13 added, 14 removed. Backfill posture.
A compelling opportunity for clinical operations, manufacturing, and regulatory professionals seeking exposure to multiple Phase 3 catalysts in rare neurology; higher risk for core R&D or discovery scientists due to lack of transparency on funding and sustainability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Praxis Precision Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Praxis Precision Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies - NeurologyLive
Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies NeurologyLive
Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight - The Malaysian Reserve
Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight The Malaysian Reserve
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive - Investor's Business Daily
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive Investor's Business Daily
Why Is Praxis Stock Plunging Today - Praxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Why Is Praxis Stock Plunging Today - Praxis Precision Medicine (NASDAQ:PRAX) Benzinga
Praxis Precision Medicines announced that its drug Vormatrigine demonstrated good tolerability in clinical trials. - Bitget
Praxis Precision Medicines announced that its drug Vormatrigine demonstrated good tolerability in clinical trials. Bitget
Praxis Precision Medicines Advances Multi Asset Pipeline After FDA NDA Acceptances - simplywall.st
Praxis Precision Medicines Advances Multi Asset Pipeline After FDA NDA Acceptances simplywall.st
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles